Core Insights - Beyond Air, Inc. is set to report its financial results for the first fiscal quarter ending June 30, 2025, on August 12, 2025, with a conference call scheduled for 4:30 PM ET [1] - The company focuses on utilizing nitric oxide to enhance the treatment of patients with respiratory illnesses, neurological disorders, and solid tumors [3][4] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company that has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating hypoxic respiratory failure in neonates [3] - The company is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] - Beyond Air has partnered with The Hebrew University of Jerusalem to develop a pre-clinical program for autism spectrum disorder and other neurological disorders [4] - An affiliate, Beyond Cancer, is investigating ultra-high concentrations of nitric oxide for targeting solid tumors in pre-clinical settings [4]

Core Insights - Beyond Air, Inc. is set to report its financial results for the fiscal fourth quarter and full year ending March 31, 2025, on June 17, 2025 [1] - The company specializes in medical devices and biopharmaceuticals, focusing on nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [3][4] Financial Reporting - The financial results will be discussed in a conference call and webcast scheduled for June 17, 2025, at 4:30 PM Eastern Time [1][2] - The conference call can be accessed via domestic and international phone lines, with a conference ID provided for participants [2] Company Overview - Beyond Air has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating neonates with hypoxic respiratory failure [3] - The company is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] - A partnership with The Hebrew University of Jerusalem is focused on pre-clinical programs for autism spectrum disorder and other neurological disorders [4] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of nitric oxide for targeting solid tumors in pre-clinical settings [4]

Company Overview - NeuroNOS is a biopharmaceutical company focused on developing treatments for complex neurological disorders, including Autism Spectrum Disorder, brain cancers, and Alzheimer's disease [1][9] - The company is a subsidiary of Beyond Air (NASDAQ: XAIR) and has established a drug development platform aimed at addressing critical gaps in treatment options for neurological conditions [1][10] Recent Research and Developments - NeuroNOS announced the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in the journal Translational Psychiatry, which presents evidence of a novel mechanism in the early stages of Alzheimer's disease [1][3] - The research identifies significant disruptions in nitric oxide (NO)-related pathways and suggests that targeted inhibition of NO production may serve as a promising therapeutic strategy for early-stage Alzheimer's disease [3][4] Market Opportunity - The global brain therapeutics market is substantial and growing, driven by an aging population and increasing prevalence of neurological disorders, with significant unmet medical needs [7] - NeuroNOS's innovative approach positions the company to capitalize on this expanding market by addressing critical treatment gaps for complex brain diseases [7] Strategic Collaborations and Intellectual Property - NeuroNOS has filed five patent families to protect its novel approach and is collaborating with leading international partners for the production of active pharmaceutical ingredients and advanced formulations [4][5] - The company's scientific team includes experts from top hospitals and institutions, including the Hebrew University of Jerusalem, which plays a central role in its research and development efforts [6][10] Clinical Development Plans - NeuroNOS is preparing for clinical trials, with plans to initiate first-in-human trials for autism in the United States in 2026 [4][8] - The company has previously achieved preclinical breakthroughs in autism and glioblastoma models, reinforcing the versatility of its nitric oxide modulation platform [8]